Study of the mechanisms of aldosterone prothrombotic effect in rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 430-439

  Gromotowicz, Anna ^a   Szemraj, Janusz ^b   Stankiewicz, Adrian ^a   Zakrzeska, Agnieszka ^a   Mantur, Maria ^a   Jaroszewicz, Ewa ^a   Rogowski, Franciszek ^a   Chabielska, Ewa ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aldosterone; eplerenone; haemostasis; rat; thrombosis

Indexed keywords

ALDOSTERONE; EPLERENONE; HYDROGEN PEROXIDE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; FIBRINOLYSIS; HEMOSTASIS; NONHUMAN; OXIDATIVE STRESS; POTASSIUM URINE LEVEL; PROTEIN EXPRESSION; RAT; THROMBOCYTE ADHESION; THROMBOGENESIS; VEIN THROMBOSIS;

ALDOSTERONE; ANIMALS; AORTA; BIOLOGICAL AVAILABILITY; BLEEDING TIME; HEMODYNAMICS; HEMOSTASIS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ADHESIVENESS; POTASSIUM; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; THROMBOSIS; VENOUS THROMBOSIS;

EID: 83455219401     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310397405     Document Type: Article

References (53)

1. Charloux A, Gronfier C, Lonsdorfer-Wolf E, et al. Aldosterone release during the sleep-wake cycle in humans. Am J Physiol. 1999 ; 276: 43-49
2. Cugini P, Lucia P. Circadian rhythm of the rennin-angiotensin-aldosterone system: a summary of our research studies. Clin Ter. 2004 ; 155: 287-291 (Pubitemid 44905215)
3. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987 ; 11: 1514-1518 (Pubitemid 17076236)
4. Grimaudo V, Hauert J, Bachmann F, et al. Diurnal variation of the fibrinolytic system. Thromb Haemost. 1988 ; 16: 495-499
5. Scherpereel P, Robelet D, Castaner M, et al. Post-operative hyperaldosteronism and related endocrine perturbations. Anesth Analg. 1979 ; 36: 117-123 (Pubitemid 9187373)
6. Udelsman R, Holbrook NJ. Endocrine and molecular responses to surgical stress. Curr Probl Surg. 1994 ; 8: 653-720
7. Struthers AD. Aldosterone: Cardiovascular assault. Am Heart. 2002 ; 144: 2-7
8. Chander PN, Rocha R, Ranaudo J, et al. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003 ; 14: 1990-1997 (Pubitemid 36909906)
9. Bodary PF, Sambaziotis C, Wickenheiser KJ, et al. Aldosterone promotes thrombosis formation after arterial injury in mice. Arterioscler Thromb Vasc Biol. 2006 ; 26: 233 (Pubitemid 43732256)
10. Stankiewicz A, Gromotowicz A, Szemraj J, et al. Acute aldosterone infusion enhances thrombosis development in normotensive rats. Thromb Haemost. 2007 ; 98: 697-699 (Pubitemid 47412905)
11. Moraes L, Paul-Clark MJ, Rickman A, et al. Ligand-specific glucocorticoid receptor activation in human platelets. Blood. 2005 ; 106: 4167-4175 (Pubitemid 41775923)
12. Schäfer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost. 2003 ; 89: 1024-1030 (Pubitemid 36798154)
13. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci. 2002 ; 103: 425-431 (Pubitemid 35193248)
14. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost. 1987 ; 58: 1078-1084
15. Reyers I, De Gaetano G, Donati MB. Venostasis-induced thrombosis in rats is not influenced by circulating platelet or leukocyte number. Agents Actions. 1989 ; 28: 137-141 (Pubitemid 19196749)
16. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost. 1982 ; 48: 108-111 (Pubitemid 12059137)
17. Mant MJ. Platelet adherence to collagen: a simple, reproducible, quantitative method for its measurement. Thromb Res. 1977 ; 11: 729-737 (Pubitemid 8251848)
18. Winer J, Jung CK, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999 ; 15: 41-49 (Pubitemid 29230718)
19. Thohan V, Torre-Amione G, Koerner MM. Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Curr Opin Cardiol. 2004 ; 19: 301-308 (Pubitemid 38916485)
20. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004 ; 351: 33-41
21. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998 ; 273: 4883-4891 (Pubitemid 28108638)
22. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 ; 82: 1730-1736 (Pubitemid 20367976)
23. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998 ; 98: 1510-1516 (Pubitemid 28481667)
24. Lin H, Young DB. Interaction between plasma potassium and epinephrine on coronary thrombosis in dogs. Circulation. 1994 ; 89: 331-338 (Pubitemid 24026507)
25. Young DB, Ma G. Vascular protective effects of potassium. Semin Nephrol. 1999 ; 19: 477-486 (Pubitemid 29451201)
26. Milner PC, Martin JF. Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J. 1985 ; 290: 1767-1770 (Pubitemid 15059204)
27. Heindl S, Holzschneider J, Hinz A, et al. Acute effects of aldosterone on the autonomic nervous system and the baroreflex function in healthy humans. J Neuroendocrinol. 2006 ; 18: 115-121
28. Enomoto S, Yoshiyama M, Omura T, et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart. 2005 ; 91: 1595-1600 (Pubitemid 41697604)
29. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000 ; 58: 1219-1227
30. Yuan J, Jia R, Bao Y. Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol. 2007 ; 40: 180-188 (Pubitemid 46515196)
31. Chun TY, Pratt JH. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol Cell Endocrinol. 2005 ; 239: 55-61 (Pubitemid 40848729)
32. Gromotowicz A, Szemraj J, Stankiewicz A, et al. Short-term aldosterone infusion disturbs endothelium-dependent haemostatic balance during experimental thrombosis in rats. Basic Clin Pharmacol. 2008 ; 102: 22
33. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002 ; 39: 351-358 (Pubitemid 34084645)
34. Peire MA, Puig-Parellada P. Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. Pharmacol Res. 1998 ; 38: 353-356 (Pubitemid 28515506)
35. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006 ; 48: 165-171 (Pubitemid 44297539)
36. Ikeda U, Kanale T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cell induced by interleukin-1β. Eur J Pharmacol. 1995 ; 290: 69-73
37. Swiatkowska M, Cierniewska-Cieslak A, Pawlowska Z, et al. Dual regulatory effects of nitric oxide on plasminogen activator inhibitor type-1 expression in endothelial cells. Eur J Biochem. 2000 ; 267: 1001-1007 (Pubitemid 30108317)
38. Simon DI, Stamler JS, Loh E, et al. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol. 1995 ; 26: 339-342
39. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005 ; 16: 2906-2912 (Pubitemid 44743488)
40. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002 ; 161: 1773-1781 (Pubitemid 35265535)
41. Iglarz M, Touyz RM, Viel EC, et al. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the rennin-angiotensin system. Am J Hypertens. 2004 ; 17: 597-603 (Pubitemid 38844986)
42. Yao SK, Ober JC, Gonenne A, et al. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res. 1993 ; 73: 952-967 (Pubitemid 23306140)
43. Mutoh A, Nishimito M, Isshiki M, et al. Low-dose eplerenone down-regulates caveolin-1 and improves endothelial function by mechanisms independent of MR antagonism. Circulation. 2008 ; 118: 366
44. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002 ; 105: 2212-2216 (Pubitemid 34517167)
45. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000 ; 15: 594-597 (Pubitemid 30094728)
46. Stankiewicz A, Gromotowicz A, Szemraj J, et al. The influence of dual renin-angiotensin-aldosterone system blockade on haemostasis in renovascular hypertensive rat. Kardiol Pol. 2008 ; 10: 385
47. Ma J, Albornoz F, Yu C, et al. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension. 2005 ; 46: 313-320 (Pubitemid 41099163)
48. Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk?. Cardiovasc Res. 2004 ; 64: 217-226 (Pubitemid 39361682)
49. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000 ; 85: 336-344 (Pubitemid 32268835)
50. Mogielnicki A, Chabielska E, Pawlak R, et al. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost. 2005 ; 93: 1069-1076 (Pubitemid 40823510)
51. Connell JM, Davis E. The new biology of aldosterone. J Endocrinol. 2005 ; 186: 1-20 (Pubitemid 41015660)
52. Chun T, Pratt HJ. Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol Metab. 2004 ; 15: 353-354 (Pubitemid 39223340)
53. Zidek W, Losse H, Schmidt W, et al. Potassium load in spontaneously hypertensive rats. Effects on blood pressure, renin-angiotensin, aldosterone, and intracellular electrolytes. Res Exp Med. 1983 ; 183: 147-152 (Pubitemid 14247754)